Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) – Pipeline Review, H1 2017’, provides in depth analysis on Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Immunology, Dermatology, Oncology, Gastrointestinal, Musculoskeletal Disorders, Central Nervous System, Hematological Disorders, Respiratory, Cardiovascular and Ophthalmology under development targeting Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)

The report reviews Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AbbVie Inc

Aclaris Therapeutics Inc

Advinus Therapeutics Ltd

Astellas Pharma Inc

AstraZeneca Plc

Chipscreen Biosciences Ltd

CJ HealthCare Corp

Eli Lilly and Company

Galapagos NV

Incyte Corp

Japan Tobacco Inc

Jiangsu Hengrui Medicine Co Ltd

Nissan Chemical Industries Ltd

Pfizer Inc

Portola Pharmaceuticals Inc

Sareum Holdings Plc

Theravance Biopharma Inc

Vectura Group Plc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Introduction 8

Global Markets Direct Report Coverage 8

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Overview 9

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Therapeutics Development 10

Products under Development by Stage of Development 10

Products under Development by Therapy Area 11

Products under Development by Indication 12

Products under Development by Companies 17

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Therapeutics Assessment 25

Assessment by Mechanism of Action 25

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Companies Involved in Therapeutics Development 29

AbbVie Inc 29

Aclaris Therapeutics Inc 29

Advinus Therapeutics Ltd 30

Astellas Pharma Inc 31

AstraZeneca Plc 31

Chipscreen Biosciences Ltd 32

CJ HealthCare Corp 32

Eli Lilly and Company 33

Galapagos NV 34

Incyte Corp 34

Japan Tobacco Inc 37

Jiangsu Hengrui Medicine Co Ltd 37

Nissan Chemical Industries Ltd 38

Pfizer Inc 38

Portola Pharmaceuticals Inc 39

Sareum Holdings Plc 40

Theravance Biopharma Inc 41

Vectura Group Plc 41

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Drug Profiles 42

ABBV-599 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

ATI-50001 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

ATI-50002 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

AZD-0449 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

AZD-1480 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

AZD-4205 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

baricitinib - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

cerdulatinib - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

CS-944X - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

filgotinib - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

INCB-52793 - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

itacitinib adipate - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

JTE-052 - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

NIP-565 - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

peficitinib hydrobromide - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

PF-04965842 - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

PF-06700841 - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

PNQ-401 - Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

PNQ-701 - Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

ruxolitinib phosphate - Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

SAR-20347 - Drug Profile 106

Product Description 106

Mechanism Of Action 106

R&D Progress 106

SART-29 - Drug Profile 108

Product Description 108

Mechanism Of Action 108

R&D Progress 108

SHR-0302 - Drug Profile 109

Product Description 109

Mechanism Of Action 109

R&D Progress 109

Small Molecules to Inhibit Jak1 for Oncology - Drug Profile 110

Product Description 110

Mechanism Of Action 110

R&D Progress 110

Small Molecules to Inhibit Janus Kinase for Rheumatoid Arthritis - Drug Profile 111

Product Description 111

Mechanism Of Action 111

R&D Progress 111

TD-1473 - Drug Profile 112

Product Description 112

Mechanism Of Action 112

R&D Progress 112

TD-3504 - Drug Profile 114

Product Description 114

Mechanism Of Action 114

R&D Progress 114

upadacitinib tartrate - Drug Profile 115

Product Description 115

Mechanism Of Action 115

R&D Progress 115

VR-588 - Drug Profile 119

Product Description 119

Mechanism Of Action 119

R&D Progress 119

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Dormant Products 120

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Discontinued Products 121

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Product Development Milestones 123

Featured News & Press Releases 123

May 18, 2017: Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association 123

May 15, 2017: Seven abstracts on filgotinib accepted by EULAR 2017 123

May 09, 2017: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference on Malignant Lymphoma 124

May 09, 2017: AbbVie Announces Positive Phase 2 Study Results for Upadacitinib (ABT-494), an Investigational JAK1-Selective Inhibitor, in Crohn's Disease 124

May 07, 2017: Galapagos presents three posters on filgotinib in Crohn's disease at DDW 2017 125

May 05, 2017: Aclaris Therapeutics Completes Phase 1 Clinical Trial of ATI-50001 for the Treatment of Alopecia Universalis and Alopecia Totalis 126

Apr 25, 2017: Galapagos announces new Phase 2 Proof-of-Concept study with filgotinib in cutaneous lupus erythematosus 127

Apr 14, 2017: U.S. FDA Issues Complete Response Letter For Baricitinib 127

Apr 05, 2017: Galapagos doses first psoriatic arthritis patient with filgotinib 128

Apr 04, 2017: Aclaris Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Baricitnib for Hair Loss Disorders 128

Apr 04, 2017: Galapagos announces three new Phase 2 Proof-of-Concept studiesbwith filgotinib 129

Mar 10, 2017: New Phase 2 studies with filgotinib in small bowel and fistulizing Crohn's disease 129

Feb 17, 2017: Theravance Biopharma Presents Positive Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization 130

Feb 15, 2017: Additional Results From Pivotal RA-BEAM Study Published In New England Journal Of Medicine Show Baricitinib-Treated Patients Demonstrated Sustained Improvement In Rheumatoid Arthritis Compared To Adalimumab And Placebo 131

Feb 13, 2017: European Commission Approves Once-Daily Olumiant Tablets For Treatment Of Adults With Moderate-To-Severe Active Rheumatoid Arthritis 132

Appendix 133

Methodology 133

Coverage 133

Secondary Research 133

Primary Research 133

Expert Panel Validation 133

Contact Us 133

Disclaimer 134

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2017 10

Number of Products under Development by Therapy Areas, H1 2017 11

Number of Products under Development by Indications, H1 2017 12

Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017 14

Number of Products under Development by Indications, H1 2017 (Contd..2), H1 2017 15

Number of Products under Development by Indications, H1 2017 (Contd..3), H1 2017 16

Number of Products under Development by Companies, H1 2017 17

Products under Development by Companies, H1 2017 18

Products under Development by Companies, H1 2017 (Contd..1), H1 2017 19

Products under Development by Companies, H1 2017 (Contd..2), H1 2017 20

Products under Development by Companies, H1 2017 (Contd..3), H1 2017 21

Products under Development by Companies, H1 2017 (Contd..4), H1 2017 22

Products under Development by Companies, H1 2017 (Contd..5), H1 2017 23

Products under Development by Companies, H1 2017 (Contd..6), H1 2017 24

Number of Products by Stage and Mechanism of Actions, H1 2017 25

Number of Products by Stage and Route of Administration, H1 2017 27

Number of Products by Stage and Molecule Type, H1 2017 28

Pipeline by AbbVie Inc, H1 2017 29

Pipeline by Aclaris Therapeutics Inc, H1 2017 30

Pipeline by Advinus Therapeutics Ltd, H1 2017 30

Pipeline by Astellas Pharma Inc, H1 2017 31

Pipeline by AstraZeneca Plc, H1 2017 31

Pipeline by Chipscreen Biosciences Ltd, H1 2017 32

Pipeline by CJ HealthCare Corp, H1 2017 32

Pipeline by Eli Lilly and Company, H1 2017 33

Pipeline by Galapagos NV, H1 2017 34

Pipeline by Incyte Corp, H1 2017 35

Pipeline by Japan Tobacco Inc, H1 2017 37

Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017 37

Pipeline by Nissan Chemical Industries Ltd, H1 2017 38

Pipeline by Pfizer Inc, H1 2017 38

Pipeline by Portola Pharmaceuticals Inc, H1 2017 39

Pipeline by Sareum Holdings Plc, H1 2017 40

Pipeline by Theravance Biopharma Inc, H1 2017 41

Pipeline by Vectura Group Plc, H1 2017 41

Dormant Projects, H1 2017 120

Discontinued Products, H1 2017 121

Discontinued Products, H1 2017 (Contd..1), H1 2017 122

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2017 10

Number of Products under Development by Therapy Areas, H1 2017 11

Number of Products under Development by Top 10 Indications, H1 2017 12

Number of Products by Stage and Mechanism of Actions, H1 2017 25

Number of Products by Routes of Administration, H1 2017 26

Number of Products by Stage and Routes of Administration, H1 2017 26

Number of Products by Stage and Molecule Type, H1 2017 28

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports